Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cyberonics

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific's approximately $50 mil. stake in the vagus nerve stimulation technology manufacturer demonstrates the firm's interest in the potential of deep brain stimulation. The VNS device already is approved for drug-resistant epilepsy, and Cyberonics is developing the device to treat depression. Houston, Texas-based Cyberonics will host a dinner program outlining its depression regulatory timeline Sept. 24. Cyberonics was targeted for acquisition by Medtronic in 2000, but rejected a $26-per-share takeover offer (1"The Gray Sheet" Sept. 18, 2000, p. 5)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT018539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel